All In Biotech

Drug Trial Radar · NCT03617263

Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

Phase 2A, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Women With Polycystic Ovary Syndrome (PCOS)

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

60

Actual

Start

Feb 12, 2019

Primary completion

Oct 28, 2024

Study completion Oct 28, 2024

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.

Conditions

  • Non-alcoholic Fatty Liver Disease in Women With PCOS

Interventions

  • Saroglitazar Magnesium 4 mg TabletDrug

    Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.

  • PlaceboDrug

    Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hepatic Fat ContentTime frame: Baseline and Week 24

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Zydus US005

    Chandler, Arizona

  • Zydus US004

    Panorama City, California

  • Zydus US002

    San Francisco, California

  • Zydus US008

    Aurora, Colorado

  • Zydus US010

    Miami, Florida

  • Zydus US001

    Indianapolis, Indiana

  • Zydus US011

    Morehead City, North Carolina

  • Zydus US003

    Marion, Ohio

  • Zydus US015

    Hershey, Pennsylvania

  • Zydus US014

    Philadelphia, Pennsylvania

  • Zydus US013

    Austin, Texas

  • Zydus US007

    San Antonio, Texas

  • Zydus US009

    San Antonio, Texas

  • Zydus MX003

    Mexico City, Mexico

  • Zydus MX006

    Guadalajara, Jalisco, Mexico

  • Zydus MX001

    Monterrey, Nuevo León, Mexico

  • Zydus MX002

    Monterrey, Nuevo León, Mexico

  • Zydus MX005

    Culiacán, Sinaloa, Mexico

  • Zydus MX004

    Mérida, Yucatán, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.